A Novel Nonsense Mutation in Androgen Receptor Confers Resistance to CYP17 Inhibitor Treatment in Prostate Cancer

Oncotarget - United States
doi 10.18632/oncotarget.14296
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Clinical Cancer Research
Cancer ResearchOncology
2011English

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

Science
MultidisciplinaryPhilosophy of ScienceHistory
2009English

Mechanisms of Acquired Resistance to Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Androgen Receptor Splice Variant-7 Expression Emerges With Castration Resistance in Prostate Cancer

Journal of Clinical Investigation
Medicine
2018English

Erratum To: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-Independent Prostate Cancer

Urology
Urology
2016English

Looking Beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer

Advances in Andrology
2014English

Collateral Resistance to Taxanes in Enzalutamide-Resistant Prostate Cancer Through Aberrant Androgen Receptor and Its Variants

Cancer Science
Cancer ResearchMedicineOncology
2018English

Adaptive Phenotype Drives Resistance to Androgen Deprivation Therapy in Prostate Cancer

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy